DK1896460T3 - Benzofuranylderivater som 5-HT6-receptorinhibitorer - Google Patents
Benzofuranylderivater som 5-HT6-receptorinhibitorerInfo
- Publication number
- DK1896460T3 DK1896460T3 DK06763743T DK06763743T DK1896460T3 DK 1896460 T3 DK1896460 T3 DK 1896460T3 DK 06763743 T DK06763743 T DK 06763743T DK 06763743 T DK06763743 T DK 06763743T DK 1896460 T3 DK1896460 T3 DK 1896460T3
- Authority
- DK
- Denmark
- Prior art keywords
- receptor inhibitors
- benzofuranyl derivatives
- benzofuranyl
- derivatives
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0501383 | 2005-06-17 | ||
| US70652305P | 2005-08-09 | 2005-08-09 | |
| PCT/EP2006/063249 WO2006134150A1 (en) | 2005-06-17 | 2006-06-15 | Benzofuranyl derivatives as 5-ht6-receptor inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1896460T3 true DK1896460T3 (da) | 2009-11-16 |
Family
ID=36659956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06763743T DK1896460T3 (da) | 2005-06-17 | 2006-06-15 | Benzofuranylderivater som 5-HT6-receptorinhibitorer |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7582767B2 (enExample) |
| EP (1) | EP1896460B1 (enExample) |
| JP (1) | JP2008543813A (enExample) |
| KR (1) | KR20080017482A (enExample) |
| CN (1) | CN101193885B (enExample) |
| AU (1) | AU2006259082B2 (enExample) |
| BR (1) | BRPI0612746A2 (enExample) |
| CA (1) | CA2610383A1 (enExample) |
| DE (1) | DE602006008002D1 (enExample) |
| DK (1) | DK1896460T3 (enExample) |
| EA (1) | EA015671B1 (enExample) |
| ES (1) | ES2330145T3 (enExample) |
| IL (1) | IL187575A (enExample) |
| MX (1) | MX2007015988A (enExample) |
| NO (1) | NO20080354L (enExample) |
| NZ (1) | NZ563510A (enExample) |
| WO (1) | WO2006134150A1 (enExample) |
| ZA (1) | ZA200710468B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0303480D0 (sv) * | 2003-12-19 | 2003-12-19 | Biovitrum Ab | Benzofuranes |
| WO2014013014A1 (en) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
| CN103880797B (zh) * | 2014-03-26 | 2015-12-02 | 沈阳大学 | 苯并呋喃类化合物及其医药用途 |
| WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| WO2020201362A2 (en) | 2019-04-02 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| WO2020212395A1 (en) | 2019-04-16 | 2020-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
| US20250283174A1 (en) | 2022-05-16 | 2025-09-11 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation |
| WO2026093435A1 (en) | 2024-10-31 | 2026-05-07 | Institut National de la Santé et de la Recherche Médicale | Use of jak inhibitors for enhancing the potency of immunotherapy in the treament of cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3539573A (en) * | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| AU767009B2 (en) | 1998-12-11 | 2003-10-30 | Virginia Commonwealth University | Selective 5-HT6 receptor ligands |
| CN100457726C (zh) | 2001-06-11 | 2009-02-04 | 比奥维特罗姆股份公开公司 | 取代的磺酰胺化合物、其制备方法及其作为治疗cns疾病、肥胖和ⅱ型糖尿病的药物的应用 |
| RS44204A (sr) * | 2001-11-22 | 2007-06-04 | Biovitrum Ab., | Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1 |
| CN1662521A (zh) | 2002-06-20 | 2005-08-31 | 比奥维特罗姆股份公司 | 可用于治疗肥胖、ii型糖尿病和cns障碍的新化合物 |
| JP4754821B2 (ja) * | 2002-06-20 | 2011-08-24 | プロキシマゲン・リミテッド | 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物 |
| SE0303480D0 (sv) * | 2003-12-19 | 2003-12-19 | Biovitrum Ab | Benzofuranes |
-
2006
- 2006-06-05 US US11/447,524 patent/US7582767B2/en not_active Expired - Fee Related
- 2006-06-15 NZ NZ563510A patent/NZ563510A/en not_active IP Right Cessation
- 2006-06-15 CA CA002610383A patent/CA2610383A1/en not_active Abandoned
- 2006-06-15 ZA ZA200710468A patent/ZA200710468B/xx unknown
- 2006-06-15 DK DK06763743T patent/DK1896460T3/da active
- 2006-06-15 KR KR1020087001242A patent/KR20080017482A/ko not_active Ceased
- 2006-06-15 EP EP06763743A patent/EP1896460B1/en not_active Expired - Lifetime
- 2006-06-15 MX MX2007015988A patent/MX2007015988A/es active IP Right Grant
- 2006-06-15 BR BRPI0612746-0A patent/BRPI0612746A2/pt not_active IP Right Cessation
- 2006-06-15 DE DE602006008002T patent/DE602006008002D1/de not_active Expired - Lifetime
- 2006-06-15 ES ES06763743T patent/ES2330145T3/es not_active Expired - Lifetime
- 2006-06-15 AU AU2006259082A patent/AU2006259082B2/en not_active Ceased
- 2006-06-15 JP JP2008516325A patent/JP2008543813A/ja not_active Withdrawn
- 2006-06-15 WO PCT/EP2006/063249 patent/WO2006134150A1/en not_active Ceased
- 2006-06-15 CN CN2006800201432A patent/CN101193885B/zh not_active Expired - Fee Related
- 2006-06-15 EA EA200800071A patent/EA015671B1/ru not_active IP Right Cessation
-
2007
- 2007-11-22 IL IL187575A patent/IL187575A/en not_active IP Right Cessation
-
2008
- 2008-01-17 NO NO20080354A patent/NO20080354L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20080017482A (ko) | 2008-02-26 |
| NO20080354L (no) | 2008-01-17 |
| NZ563510A (en) | 2011-01-28 |
| AU2006259082B2 (en) | 2011-07-14 |
| CN101193885B (zh) | 2011-07-27 |
| EA200800071A1 (ru) | 2008-10-30 |
| JP2008543813A (ja) | 2008-12-04 |
| WO2006134150A1 (en) | 2006-12-21 |
| EP1896460A1 (en) | 2008-03-12 |
| EP1896460B1 (en) | 2009-07-22 |
| CN101193885A (zh) | 2008-06-04 |
| EA015671B1 (ru) | 2011-10-31 |
| US20060293361A1 (en) | 2006-12-28 |
| ES2330145T3 (es) | 2009-12-04 |
| MX2007015988A (es) | 2008-03-07 |
| DE602006008002D1 (de) | 2009-09-03 |
| BRPI0612746A2 (pt) | 2010-11-30 |
| IL187575A (en) | 2012-12-31 |
| US7582767B2 (en) | 2009-09-01 |
| IL187575A0 (en) | 2008-03-20 |
| AU2006259082A1 (en) | 2006-12-21 |
| HK1112918A1 (en) | 2008-09-19 |
| CA2610383A1 (en) | 2006-12-21 |
| ZA200710468B (en) | 2009-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1863474T3 (da) | Hidtil ukendte thiophenderivater som sphingosin-1-phosphat-1-receptoragonister | |
| DK1926722T3 (da) | Substituerede benzimidazoler som kinaseinhibitorer | |
| DK1789041T3 (da) | Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer | |
| DK1863818T3 (da) | Acetylenyl-pyrazolo-pyrimidinderivater som mglur2-antagonister | |
| DK1797042T3 (da) | Indozolonderivater som 11B-HSD1-inhibitorer | |
| DK1959951T3 (da) | Heteroaryl-substituerede piperidinderivater som L-CPT1-inhibitorer | |
| DK2094263T3 (da) | 2-adamantyl-butyramidderivater som selektive 11 beta-hsd1-inhibitorer | |
| DK2069310T3 (da) | Sulfonylpyrazolin-1-carboxamidin-derivater som 5-HT6-antagonister | |
| DK1846394T3 (da) | Pyrazolylaminopyridinderivater, der er egnede som kinaseinhibitorer | |
| DK2086939T3 (da) | Pyridiacarboxamid som II-beta-HSDI-inhibitorer | |
| DK2220070T3 (da) | 2-benzylpyridazinonderivater som Met-kinaseinhibitorer | |
| DK2004654T3 (da) | Pyrazolopyrimidin derivater til anvendelse som kinase antagonister | |
| DK2016080T3 (da) | Dihydropyrazolopyrimidinon-derivater | |
| ATE483711T1 (de) | Spiroindolinonderivate | |
| DK2078001T3 (da) | Diazepan-acetamidderivater som selektive 11-HSD1-inhibitorer | |
| NO20082517L (no) | Aminopyrimidiner anvendelige som kinaseinhibitorer | |
| ATE469905T1 (de) | Pyridopyrimidinonderivate | |
| DK2094709T3 (da) | Thiazol-pyrazolopyrimidiner som CRF1-receptorantagonister | |
| ATE512135T1 (de) | Spiroindolinonderivate | |
| DK1856110T3 (da) | Oxyindol derivater som 5HT4-receptor agonister | |
| DK2035394T3 (da) | 2-pyrazincarboxamidderivater | |
| BRPI0714764A2 (pt) | Derivados substituídos de sulfonamida | |
| DK2086968T3 (da) | 5-hydroxymethyl-oxazolidin-2-on-derivater | |
| DK2049480T3 (da) | 2-arylindolderivater som mPGES-1-hæmmere | |
| ATE549350T1 (de) | Neuropeptid-2-rezeptor-agonisten |